Allos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient...
05 Juin 2010 - 3:00PM
Business Wire
Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported new
analyses of data from the Company’s pivotal PROPEL trial of
FOLOTYN® (pralatrexate injection) in patients with relapsed or
refractory peripheral T-cell lymphoma (PTCL). These analyses
demonstrated that patients who responded to FOLOTYN had up to a 44%
reduction in risk of death based on independent central review of
response (P=.07), and up to a 56% reduction in risk of death based
on investigator review of response (P=
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics, Inc.